Kidney biotech R1's $78m debut, and other biofinancings Biofinancing values have tailed off a bit after a strong start to 2026, but March has seen $50m+ rounds for R1, Crossbow, Excalipoint, and Prolium.

After a strong start to the year, the value of #biotech #financings has tailed off a little, but March has seen a clutch of $50 million-plus rounds for #R1, #Crossbow, #Excalipoint, and #Prolium.

pharmaphorum.com/news/kidney-...